CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Drug Pipeline

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. maintains a substantial clinical development portfolio, with 78 trials registered since 2008, of which 32 are currently active. These active programs span from Phase 1 through Phase 3, with 12, 15, and 13 trials respectively, indicating a pipeline with potential near-term catalysts. The portfolio covers nine therapeutic areas, but is heavily concentrated in oncology, which accounts for 66% of active programs (21 trials). Within oncology, the leading indications by active trial count are breast cancer (5 active, 2 in Phase 3), non-Hodgkin lymphoma (2 active, 1 in Phase 3), advanced solid tumor (2 active), acute myeloid leukemia (AML) (2 active), and gastric cancer (2 active, 1 in Phase 3). Beyond oncology, the company also has active trials in respiratory (3 trials), metabolic, central nervous system (CNS), cardiovascular, and immunology (1 trial each).